



Updates on Highly Pathogenic Avian Influenza and Newcastle Disease

CDG on Poultry and eggs

10 October 2023

**DG Health and Food Safety
Unit G2 – Animal Health**


OUTLINE

1. Summary of HPAI epidemic seasons
2. HPAI vaccination
3. Newcastle disease situation


Summary of HPAI epidemic seasons

HPAI IN EUROPE IN BIRDS IN 2020 - 2023


Oct 2020 – Sept 2021



Oct 2021 – Sept 2022



Oct 2022 – Sept 2023



Virus spread with **wild birds** in all parts of Europe



Recurrent clusters in poultry in certain areas with high density of certain poultry production

HPAI IN EU IN BIRDS / WEEK 2020-2023

2020-2021

2021-2022

2022-2023




High peaks in poultry in the past (red line) detached from peaks in wild birds (green line)
In 2022 – 2023 epidemic: less outbreaks in poultry, but worrying trend in wild birds


HPAI in wild birds 2020 - 2023

Distribution of total number of HPAI virus detections reported in Europe by week of suspicion in **wild birds**

5 Oct 2020 – 1 Mar 2023




Summary of HPAI epidemic seasons in figures




LAST TWO WEEKS

Last week of Sept 2023



First week of Oct 2023



Limited number of HPAI virus detections in wild birds

First outbreak in poultry after summer

Vaccination against HPAI

Specific rules for vaccination against HPAI

Vaccines

- that **do not contain live AI virus** (attenuated or not)

Reinforced surveillance

- **clinical and laboratory** (official activity)
- to assess **effectiveness** (emergency protective vaccination)
- to **early detect infection** with HPAI virus

Risk mitigation measures

- General **prohibition** for movements of vaccinated poultry and their products
- **Derogations** to move, **under conditions**

Traceability/Certificates

- **Emergency vaccination:** certificates for movements from vaccination zone within MS and to other MS
- **Preventive vaccination:** certificates for poultry and hatching eggs when moved to other MS

Decision Making - Implementation process for the use of vaccines against HPAI

Member State

- **Assessment of the situation** based on specific criteria (*Annex II of DR (EU) 2023/361*)
- **DECISION TO VACCINATE** (*strategy selection etc.*)
- Preparation of official vaccination plan (*in accordance with information required in Annex III of DR (EU) 2023/361*)

Member State

- Preliminary information sent *to the other MS and the COM* (*at least 2 days before start of vaccination*)
- **INITIATION OF VACCINATION**
- Official vaccination plan sent *to the other MS and the COM* (*at the latest 2 weeks after start of vaccination*)

COM

Review of the national measures in the official vaccination plan. **May act with additional measures** in accordance with Article 71 of Regulation (EU) 2016/429

Member State

- **Disease-specific surveillance – Risk mitigation measures** (*Annex XIII of DR (EU) 2023/361*)
- **Regular reports** sent *to the other MS and the COM* (*content / intervals according to the vaccination strategy – Annexes V and VI of DR (EU) 2023/361*)

HPAI VACCINATION

experience, trials and plans

in certain EU Member States



CZECH REPUBLIC **emergency vaccination**

in 2022 in one establishment to
preserve geese of high genetic
value

HUNGARY

Field trial 2022 in geese

ITALY

vaccine efficacy trial
in turkeys in 2022

FRANCE

Preventive vaccination of
ducks
start fall 2023

NETHERLANDS

Field trial in laying hens
start fall 2023



MINISTÈRE
DE L'AGRICULTURE
ET DE LA SOUVERAINETÉ
ALIMENTAIRE
*Liberté
Égalité
Fraternité*

**64
million**

Number of Ducks




2700

Number of
establishments



Vaccination campaign map

Number of active establishments per department



France


Vaccination of
ducks

Start

October 2023

Newcastle disease situation

Newcastle disease outbreaks in 2022 and 2023



Thank you

COM web page on Avian influenza

https://ec.europa.eu/food/animals/animal-diseases/diseases-and-control-measures/avian-influenza_en



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: [element concerned](#), source: [e.g. Fotolia.com](#); Slide xx: [element concerned](#), source: [e.g. iStock.com](#)